HCC

June 26, 2020

TXR-311 has demonstrated activity in validation studies and has selectivity for killing hepatocellular carcinoma tumor cells.

June 05, 2020

Richard S. Finn, MD, discusses how he sees the field of hepatocellular carcinoma evolving in the future.

June 01, 2020

In a Targeted Oncology case-based peer perspectives live discussion, David H. Ilson, MD, PhD, discusses the treatment options for patients with hepatocellular carcinoma

May 29, 2020

“For the first-time we have a regimen that markedly improves survival over sorafenib, the standard of care for first-line hepatocellular carcinoma since 2007, and offers patients the opportunity for improved disease control with a favorable tolerability profile.”

May 20, 2020

David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.

May 19, 2020

Based on data from a matching-adjusted indirect comparison study, cabozantinib the safety and efficacy of cabozantinib may be comparative to regorafenib in advanced hepatocellular carcinoma.

May 13, 2020

In an interview with Targeted Oncology, Yujin Hoshida, MD, PhD, discussed the next steps for improving upon the current understanding of hepatocellular carcinoma subtypes to improve responses and outcomes in patients.

May 07, 2020

Anjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.

May 06, 2020

"Having obtained an encouraging proof-of-concept for the liver-cancer directed effect of MIV-818 in phase Ia, we hope to get additional supportive data from the phase Ib study. We believe that MIV-818 has the potential to provide liver cancer patients with major therapeutic benefits."

April 24, 2020

“If we’re going to get patients to second-line treatment, we have to get them to front line. That has to do with transitioning patients from locoregional therapy appropriately."